Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
13. Februar 2025 08:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
11. Februar 2025 09:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
07. Februar 2025 08:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
28. Januar 2025 05:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
23. Januar 2025 08:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
22. Januar 2025 08:00 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
12. Dezember 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics Approach
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
21. November 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
19. November 2024 16:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
04. November 2024 07:30 ET
|
Conduit Pharmaceuticals
Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656,...